Bioavailability Enhancement in Early Formulation Development

3/10/2020 09:30 - 10:05

  • Options for BA-enhancement in early formulation development
  • Case studies for preclinical and early clinical use
  • Reference to rDCS and comparison, which option most promising based on compound properties

Please note that this will be a remote presentation

Ildiko Terebesi, Head of Drug Delivery Innovation, Bayer